Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
about
Unmet Needs in LDL-C Lowering: When Statins Won't Do!PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumabPCSK9 inhibitors in the prevention of cardiovascular diseasePCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic eraPCSK9 Inhibition With Monoclonal Antibodies: Modern Management of HypercholesterolemiaPCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to dateLDL-Cholesterol: Standards of Treatment 2016: A German Perspective.Effect of alirocumab dose increase on LDL lowering and lipid goal attainment in patients with dyslipidemia.Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBBiology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.Systematic review of published Phase 3 data on anti-PCSK9 monoclonal antibodies in patients with hypercholesterolaemia.Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical ConsiderationsEfficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.Reductions in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 ODYSSEY Trials Comparing Alirocumab With Control.Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.Lowering serum lipids via PCSK9-targeting drugs: current advances and future perspectives.Efficacy of alirocumab according to background statin type and dose: pooled analysis of 8 ODYSSEY Phase 3 clinical trialsAlirocumab: First Global Approval.Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials.Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.An evaluation of alirocumab for the treatment of hypercholesterolemia.Anti-PCSK9 antibodies for hypercholesterolaemia: Overview of clinical data and implications for primary care.Alirocumab for hyperlipidemia: ODYSSEY Phase III clinical trial results and US FDA approval indications.Emerging biologic therapies for hypercholesterolaemia.PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: alirocumab.Alirocumab: A Review in Hypercholesterolemia.New directions for pharmacotherapy in the treatment of acute coronary syndrome.Future Lipid-Altering Therapeutic Options Targeting Residual Cardiovascular Risk.Alirocumab for the treatment of hypercholesterolaemia.Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).Alirocumab for the treatment of hypercholesterolemia.Management of Hypercholesterolemia, Appropriateness of Therapeutic Approaches and New Drugs in Patients with High Cardiovascular Risk.Novel Therapies for Familial Hypercholesterolemia.Target-Mediated Drug Disposition Population Pharmacokinetics Model of Alirocumab in Healthy Volunteers and Patients: Pooled Analysis of Randomized Phase I/II/III Studies.PCSK9 inhibitors: A new era of lipid lowering therapy.PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis.
P2860
Q26741705-A814A2B6-13B5-41BB-96F2-BD979E8F1241Q26747776-8E585D92-39F4-4DE7-B7FB-8E2183E1B38BQ28071452-68EFAEF3-654D-4DC0-9B9A-3DB4D8F7F6D8Q28073656-7FEA212A-471E-445E-B1D3-4695C85A2994Q28275648-8C52FAA9-5A58-412B-A0C2-C66E53690AA0Q30234612-B0AAF343-A763-46B7-AA02-0B576F728E3BQ30244599-47176886-B5CF-4FBA-AE6F-F1058F5EAFE2Q30248925-8C5DE9CA-9064-465A-B30E-EC87CD61291FQ33590874-83E571C3-A450-4FD4-8780-093EBFC1CA89Q33808620-09AD5BB1-3781-4F4D-9BEB-BD19E8966550Q33908782-F1BC2955-AC77-4F44-BC8E-7FC780FD0E9AQ34536594-CF4340A5-9A56-4D49-9FC0-40F38278D1E0Q35999550-9A5B160A-85AE-473F-AC1F-D4708470E146Q36091331-83792E13-0B18-4C4A-B0E2-AF14E1C95AD3Q36130225-F32E40D3-3141-4112-AAD7-58902966AD67Q37011769-DE72D83B-FFDF-4B78-AB7E-7F4EE018C4CDQ37364393-E38AD00C-8C9C-4BDC-BD74-6529AA4C81B3Q37488469-A903822E-D446-4B8E-BE49-A205A5B66222Q37584256-3074622B-1534-4DE9-AC8D-49567419CFC2Q37688760-F1E45AA8-9AE3-4F35-9D33-BB9889B1EA31Q37736674-917304FB-ABE4-41D6-87AD-26D066F93BB1Q38586794-F7C35531-44D4-436F-AB83-3301A3E3ACA1Q38597940-F89121EF-175A-46AB-BE54-DC064C2BDA9DQ38631018-4BF7F331-7774-4FEA-97F2-CB6EECC9F53BQ38632198-EAC8994D-A0A9-4A03-805A-CE728A7737C1Q38657213-DD29C5D6-3BB2-4579-AF32-6A1792304C0EQ38702989-422BF9CD-0D4B-4CD8-B3BC-DAD12CD0509CQ38724666-865C4469-4629-4E73-8BBA-57785D926AC8Q38748829-24373109-A515-4186-B86F-74261D1396DAQ38758372-C110AF13-DF2C-41E6-B4F9-885A57A653AAQ38817144-2D1734F0-EC1A-449C-9072-9EDC8C86DA6DQ38842531-E668D239-A423-4C9F-8E46-13BB9B00A4C6Q38843982-EE287A1C-50B8-4583-9F13-D9ADB1C8350DQ38846832-DE11BD8D-96F1-4114-A6F5-58460A434333Q38917894-B33B568F-6C23-45D7-B5E8-0B4215C8A60FQ38938935-D21DC385-856C-41BA-8E8F-E8D87386F972Q38952663-37F5357F-9351-4672-959A-5A052D8E6497Q39034676-29A5A3EF-B967-4BCF-8D92-1B19FF1A3382Q39176815-82FC2066-D0D4-49C9-9717-E609D1AB1275Q39427680-6C9B750F-9A4B-4608-9A45-E03A02DA38F8
P2860
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Alirocumab as Add-On to Atorva ...... EY OPTIONS I Randomized Trial.
@ast
Alirocumab as Add-On to Atorva ...... EY OPTIONS I Randomized Trial.
@en
type
label
Alirocumab as Add-On to Atorva ...... EY OPTIONS I Randomized Trial.
@ast
Alirocumab as Add-On to Atorva ...... EY OPTIONS I Randomized Trial.
@en
prefLabel
Alirocumab as Add-On to Atorva ...... EY OPTIONS I Randomized Trial.
@ast
Alirocumab as Add-On to Atorva ...... EY OPTIONS I Randomized Trial.
@en
P2093
P2860
P356
P1476
Alirocumab as Add-On to Atorva ...... SEY OPTIONS I Randomized Trial
@en
P2093
Corinne Hanotin
Daniel Gaudet
Harold Bays
Ioanna Gouni-Berthold
Jennifer Robinson
Juan Lima Ruiz
Robert Weiss
Stephen Donahue
P2860
P304
P356
10.1210/JC.2015-1520
P407
P50
P577
2015-06-01T00:00:00Z